Fluid biomarker and electrophysiological outcome measures for progressive MS trials
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fluid biomarker and electrophysiological outcome measures for progressive MS trials
Authors
Keywords
-
Journal
Multiple Sclerosis Journal
Volume 23, Issue 12, Pages 1600-1613
Publisher
SAGE Publications
Online
2017-10-18
DOI
10.1177/1352458517732844
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis
- (2017) I. Håkansson et al. EUROPEAN JOURNAL OF NEUROLOGY
- Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
- (2017) Diego Cadavid et al. LANCET NEUROLOGY
- A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS
- (2017) Martin Hardmeier et al. Multiple Sclerosis Journal
- Brain-derived neurotrophic factor levels under chronic natalizumab treatment in multiple sclerosis. A preliminary report
- (2017) Vitalie Văcăraş et al. Neurologia i Neurochirurgia Polska
- Serum neurofilament is associated with progression of brain atrophy and disability in early MS
- (2017) Jens Kuhle et al. NEUROLOGY
- Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
- (2017) Niklas Mattsson et al. JAMA Neurology
- A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS
- (2017) Martin Hardmeier et al. Multiple Sclerosis Journal
- Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis
- (2016) Xavier Giffroy et al. BMC Neurology
- Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
- (2016) Jens Kuhle et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis
- (2016) J. Mellergård et al. EUROPEAN JOURNAL OF NEUROLOGY
- Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis
- (2016) Lenka Novakova et al. JOURNAL OF NEUROCHEMISTRY
- YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis
- (2016) Joachim Burman et al. JOURNAL OF NEUROIMMUNOLOGY
- Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis
- (2016) M.Alba Mañé-Martínez et al. JOURNAL OF NEUROIMMUNOLOGY
- Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum
- (2016) Carlo Wilke et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
- (2016) Lenka Novakova et al. Multiple Sclerosis Journal
- Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
- (2016) Jens Kuhle et al. Multiple Sclerosis Journal
- Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab
- (2016) Pierre de Flon et al. NEUROLOGY
- Neurofilament light chain level is a weak risk factor for the development of MS
- (2016) Georgina Arrambide et al. NEUROLOGY
- Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases
- (2016) Mehtap Bacioglu et al. NEURON
- Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
- (2016) Lenka Novakova et al. Multiple Sclerosis Journal
- Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
- (2016) Jens Kuhle et al. Multiple Sclerosis Journal
- Cognitive event-related potentials in multiple sclerosis: Correlation with MRI and neuropsychological findings
- (2016) Vasilios K. Kimiskidis et al. Multiple Sclerosis and Related Disorders
- Plasma neurofilament light chain predicts progression in progressive supranuclear palsy
- (2016) Julio C. Rojas et al. Annals of Clinical and Translational Neurology
- Neurofilament light chain: a biomarker for genetic frontotemporal dementia
- (2016) Lieke H. Meeter et al. Annals of Clinical and Translational Neurology
- Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
- (2016) Magnus Gisslén et al. EBioMedicine
- Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis
- (2015) Patrick Weydt et al. ANNALS OF NEUROLOGY
- Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes
- (2015) Ester Cantó et al. BRAIN
- Evoked potentials and disability in multiple sclerosis: A different perspective to a neglected method
- (2015) Nefati Kiylioglu et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Event related potential and response time give evidence for a physiological reserve in cognitive functioning in relapsing–remitting multiple sclerosis
- (2015) Mathias Sundgren et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
- (2015) M Alba Mañé Martínez et al. Multiple Sclerosis Journal
- Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis
- (2015) G Hinsinger et al. Multiple Sclerosis Journal
- Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
- (2015) C.-H. Lu et al. NEUROLOGY
- Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
- (2015) J. Kuhle et al. NEUROLOGY
- Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
- (2015) M Alba Mañé Martínez et al. Multiple Sclerosis Journal
- Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis
- (2015) G Hinsinger et al. Multiple Sclerosis Journal
- Multimodal neurophysiological evaluation of primary progressive multiple sclerosis – An increasingly valid biomarker, with limits
- (2015) L.J.W. Canham et al. Multiple Sclerosis and Related Disorders
- Assessing tissue damage in multiple sclerosis: a biomarker approach
- (2014) J. Burman et al. ACTA NEUROLOGICA SCANDINAVICA
- Reproducibility of multifocal visual evoked potential and traditional visual evoked potential in normal and multiple sclerosis eyes
- (2014) Divya Narayanan et al. DOCUMENTA OPHTHALMOLOGICA
- Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis
- (2014) L. M. Villar et al. EUROPEAN JOURNAL OF NEUROLOGY
- N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis
- (2014) Alessandro Trentini et al. JOURNAL OF NEUROLOGY
- Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients
- (2014) M. M. Gresle et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- No evidence for an association of osteopontin plasma levels with disease activity in multiple sclerosis
- (2014) Tessel F Runia et al. Multiple Sclerosis Journal
- Optical coherence tomography and visual evoked potentials: which is more sensitive in multiple sclerosis?
- (2014) Giovanni Di Maggio et al. Multiple Sclerosis Journal
- Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial
- (2014) J. Romme Christensen et al. NEUROLOGY
- Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis
- (2013) J. Kuhle et al. ACTA NEUROLOGICA SCANDINAVICA
- Central motor conduction time may predict response to fampridine in patients with multiple sclerosis
- (2013) D. Zeller et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis–osteopontin as a potential marker of clinical severity
- (2013) Levente Szalardy et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Body fluid biomarkers in multiple sclerosis
- (2013) Manuel Comabella et al. LANCET NEUROLOGY
- Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis
- (2013) Regina Schlaeger et al. Multiple Sclerosis Journal
- Evoked potentials are of little use in the diagnosis or monitoring of MS: No
- (2013) Oscar Fernández et al. Multiple Sclerosis Journal
- CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions
- (2013) Enrique Alvarez et al. Multiple Sclerosis Journal
- Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development
- (2013) Pia Kivisäkk et al. Multiple Sclerosis Journal
- Cortical plasticity predicts recovery from relapse in multiple sclerosis
- (2013) Francesco Mori et al. Multiple Sclerosis Journal
- Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
- (2013) Markus Axelsson et al. Multiple Sclerosis Journal
- A comparative study of CSF neurofilament light and heavy chain protein in MS
- (2013) Jens Kuhle et al. Multiple Sclerosis Journal
- Retest Reliability of Individual P3 Topography Assessed by High Density Electroencephalography
- (2013) Manuel Vázquez-Marrufo et al. PLoS One
- Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression
- (2013) Sharmilee Gnanapavan et al. PLoS One
- Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
- (2013) Johanna Gaiottino et al. PLoS One
- Relationship between Cerebrospinal Fluid Biomarkers for Inflammation, Demyelination and Neurodegeneration in Acute Optic Neuritis
- (2013) Signe Modvig et al. PLoS One
- Serum GFAP levels in optic neuropathies
- (2012) Mithu Storoni et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study
- (2012) Peter Connick et al. LANCET NEUROLOGY
- CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis
- (2012) Jeppe Romme Christensen et al. Multiple Sclerosis Journal
- CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome
- (2012) M Khalil et al. Multiple Sclerosis Journal
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid
- (2011) Samia Ragheb et al. Multiple Sclerosis Journal
- Simvastatin improves final visual outcome in acute optic neuritis: a randomized study
- (2011) Anna Tsakiri et al. Multiple Sclerosis Journal
- The Use of Serum Glial Fibrillary Acidic Protein Measurements in the Diagnosis of Neuromyelitis Optica Spectrum Optic Neuritis
- (2011) Mithu Storoni et al. PLoS One
- Evidence for acute neurotoxicity after chemotherapy
- (2010) Axel Petzold et al. ANNALS OF NEUROLOGY
- Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
- (2010) Martin Gunnarsson et al. ANNALS OF NEUROLOGY
- Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis
- (2010) Manuel Comabella et al. BRAIN
- Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis
- (2010) M. Axelsson et al. JOURNAL OF NEUROLOGY
- Neurofilament light as a prognostic marker in multiple sclerosis
- (2010) Jonatan Salzer et al. Multiple Sclerosis Journal
- Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis
- (2010) Lars Börnsen et al. Multiple Sclerosis Journal
- Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
- (2010) Mohsen Khademi et al. Multiple Sclerosis Journal
- Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations
- (2010) David M Rissin et al. NATURE BIOTECHNOLOGY
- Astrocytic damage is far more severe than demyelination in NMO: A clinical CSF biomarker study
- (2010) R. Takano et al. NEUROLOGY
- The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS)
- (2010) Johannes Brettschneider et al. PLoS One
- The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers
- (2009) M. Khademi et al. EUROPEAN JOURNAL OF NEUROLOGY
- Serum levels of CXCL13 are elevated in active multiple sclerosis
- (2009) Eugene D Festa et al. Multiple Sclerosis Journal
- Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS
- (2009) F. Sellebjerg et al. NEUROLOGY
- Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis
- (2009) C. E. Teunissen et al. NEUROLOGY
- Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse
- (2009) Elizabeth Regina Comini Frota et al. NEUROSCIENCE LETTERS
- Multifocal VEP and OCT in optic neuritis: a topographical study of the structure–function relationship
- (2008) Alexander Klistorner et al. DOCUMENTA OPHTHALMOLOGICA
- A comparison of multifocal and conventional visual evoked potential techniques in patients with optic neuritis/multiple sclerosis
- (2008) Larissa K. Grover et al. DOCUMENTA OPHTHALMOLOGICA
- Phosphorylation and compactness of neurofilaments in multiple sclerosis: Indicators of axonal pathology
- (2008) Axel Petzold et al. EXPERIMENTAL NEUROLOGY
- The Phosphorylated Axonal Form of the Neurofilament Subunit NF-H (pNF-H) as a Blood Biomarker of Traumatic Brain Injury
- (2008) Kevin J. Anderson et al. JOURNAL OF NEUROTRAUMA
- Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event
- (2008) J.-C. Corvol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started